Invivyd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bill Duke

최고 경영자

US$635.5k

총 보상

CEO 급여 비율	75.53%
CEO 임기	1.7yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

CEO 보상 분석

Bill Duke 의 보수는 Invivyd 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	-US$143m
Dec 31 2024	US$636k	US$480k	-US$170m

보상 대 시장: Bill 의 총 보상 ($USD 635.54K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 645.80K ).

보상과 수익: Bill 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Bill Duke (52 yo)

1.7yrs

테뉴어

US$635,543

보상

Mr. William E. Duke, Jr., also known as Bill, M.B.A., serves as Chief Financial Officer and Principal Accounting Officer of Invivyd, Inc. since September 2023 and serves as its Principal Executive Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Duke	CFO, Principal Accounting Officer & Principal Executive Officer	1.7yrs	US$635.54k	데이터 없음
Julie Green	Chief Human Resources Officer & Head of Communications	2.3yrs	US$1.59m	0% $ 0
Timothy Lee	Chief Commercial Officer	1yr	US$1.20m	0% $ 0
Robert Allen	Chief Scientific Officer	2.1yrs	US$2.16m	0% $ 0
Scott Young	Senior Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Jill Andersen	Chief Legal Officer & Corporate Secretary	3.5yrs	US$2.08m	0.0022% $ 2.1k
Mark Wingertzahn	Senior Vice President of Clinical Development & Medical Affairs	1.3yrs	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: IVVD 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Terrance McGuire	Independent Director	4.6yrs	US$109.27k	0% $ 0
Kevin McLaughlin	Independent Director	1yr	US$167.33k	0% $ 0
Marc Elia	Independent Chairperson of the Board	2.9yrs	US$150.77k	0% $ 0
Ajay Royan	Independent Director	less than a year	US$19.01k	데이터 없음
Christine Lindenboom	Independent Director	2.6yrs	US$157.60k	0% $ 0
Srishti Gupta	Independent Director	1yr	US$164.26k	0% $ 0
Tamsin Berry	Independent Director	2.9yrs	US$109.87k	0% $ 0

2.6yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: IVVD 의 이사회는 경험(평균 재직 기간 2.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/22 17:07
장 마감 주가	2025/05/22 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Invivyd, Inc. 4 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jason Kolbert	D. Boral Capital LLC.
Patrick Trucchio	H.C. Wainwright & Co.
Michael Yee	Jefferies LLC

Invivyd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Invivyd, Inc., Annual General Meeting, May 21, 2024

Recent updates

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc. Announces Resignation of Anand Shah from the Board of Directors and All Committees